Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
101 studies found for:    Gd-DTPA
Show Display Options
Rank Status Study
1 Completed
Has Results
Multihance at 3 Tesla in Brain Tumors
Condition: Brain Tumor
Interventions: Drug: Multihance;   Drug: Arm 2 - Magnevist
2 Terminated
Has Results
Safety and Efficacy of MultiHance in Pediatric Patients
Condition: Central Nervous System Diseases
Intervention: Drug: gadobenate dimeglumine
3 Completed Magnevist Post-marketing Surveillance in Japan
Condition: Diagnostic Imaging
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
4 Completed Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI
Condition: Hepatocellular Carcinoma
Intervention: Drug: gadobenate dimeglumine (MultiHance)
5 Active, not recruiting Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
Condition: Liver Tumor
Interventions: Drug: MRI with Multihance;   Drug: MRI with Eovist
6 Completed Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain
Condition: Brain Lesions
Interventions: Drug: MULTIHANCE:;   Drug: GADOVIST
7 Completed
Has Results
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Conditions: Fibrosis;   Kidney Failure;   Renal Insufficiency
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
8 Completed
Has Results
Contrast-enhanced MRI in Children 2 Months to <2 Years
Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-6661)
9 Completed Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Conditions: Magnetic Resonance Angiography;   Peripheral Vascular Diseases;   Peripheral Arterial Diseases
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)
10 Completed Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis
Condition: Brain Neoplasms
Intervention: Drug: Magnevist (SH L 451A)
11 Withdrawn Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?
Condition: Meniere Disease
Intervention: Drug: Gadopentetate dimeglumine
12 Completed A Pharmacokinetics Study of MultiHance in Pediatric Patients
Condition: Central Nervous System Pathology
Intervention: Drug: Multihance
13 Completed Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries
Condition: Peripheral Vascular Disease
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
14 Terminated Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
Conditions: Adult Anaplastic (Malignant) Meningioma;   Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Choroid Plexus Neoplasm;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade II Meningioma;   Adult Medulloblastoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Adult Papillary Meningioma;   Adult Pineal Gland Astrocytoma;   Adult Pineoblastoma;   Adult Primary Melanocytic Lesion of Meninges;   Adult Supratentorial Primitive Neuroectodermal Tumor;   Malignant Adult Intracranial Hemangiopericytoma;   Metastatic Malignant Neoplasm in the Brain;   Multiple Sclerosis;   Recurrent Adult Brain Neoplasm
Interventions: Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Drug: Gadobenate Dimeglumine;   Drug: Gadobutrol;   Radiation: Gadopentetate Dimeglumine
15 Completed Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries
Condition: Carotid, Aortic, Renal or Peripheral Artery Disease
Interventions: Drug: Gadobenate Dimeglumine;   Drug: Gadopentetate Dimeglumine
16 Active, not recruiting Crossover Comparison of MultiHance and Dotarem
Condition: Brain Disease
Interventions: Drug: Gadobenate;   Drug: Gadoterate
17 Completed Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries
Condition: Stenosis
Intervention: Drug: Gadopentetate dimeglumine (Magnevist)
18 Completed Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches
Condition: Cardiovascular Abnormalities
Intervention: Drug: Gadopentetate dimeglumine (Magnevist)
19 Recruiting Liver Lesions in Contrast-Enhanced Magnetic Resonance Imaging (MRI)
Condition: Liver Neoplasms
Interventions: Drug: Gadoxetate;   Drug: Gadopentetate Dimeglumine
20 Completed Retrospective Study of MRI in Pediatric Patients
Conditions: Central Nervous System Disease;   Central Nervous System Neoplasms
Intervention: Drug: Gadobenate Dimeglumine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.